CRVS - Corvus Pharmaceuticals Inc

https://www.corvuspharma.com

Buy Momentum: Bearish

Recent News

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - Corvus Pharma ( NASDAQ:CRVS )

Benzinga • 4 months, 3 weeks ago • score: -0.16

Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology ( SID ) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025

Neutral

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - Corvus Pharma ( NASDAQ:CRVS )

Benzinga • 5 months ago • score: -0.12

SOUTH SAN FRANCISCO, Calif., April 09, 2025 ( GLOBE NEWSWIRE ) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.

52W High

$10.00

52W Low

$2.54

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.51

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.36

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

5.72

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

3.96%

Institutions (25–75% balanced)

56.19%

Shares Outstanding

74,514,000

Float

57,356,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.10

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.69%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.3918

0.4251

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025